Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 24, Issue 5, 2004, Pages 480-482

  Lv, Liqun ^a   Liu, Yi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Insulin resistance; Ovulation; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

BIOLOGICAL ORGANS; BLOOD; DRUG THERAPY; INSULIN; METABOLISM;

ENDOCRINE; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME (PCOS); ROSIGLITAZONE;

PATIENT TREATMENT;

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD; FEMALE; HUMAN; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY;

ADULT; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LUTEINIZING HORMONE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 25844467331     PISSN: 0257716X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Franks S. Polycystic ovary syndrome. N Engl J Med, 1995,333:853
2. Meirow D, Yossepowitch O, Rosier A et al. Insulin resistant and non-resistant polycystic ovary syndrome represent two clinical and endocrinological subgroups. Hum Reprod, 1995,10:1951
3. Poretsky I, Piper B. Insulin resistance. Hypersecretion of LH and a dual-detect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynccol, 1994,84:613
4. Chang B C, Zheng S X. Insulin enhanced sensitized agent-Application of rosiglitazone in diabetes mellitus. Guo Wai Yi Xue Nei Fen Mi Xue Fen Ce (Chinese), 2001,21(1):34
5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesia. Endocr Rev, 1997,18(10):774
6. Nestler J E, Daniela J, Jakubowiez M D. Decrease in ovarian cytochrome p450sc17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med, 1996,335:617
7. Leroith D, Werner H, Roberts C T et al. Molecular and cellular aspects of the insulin like growth factor-1 receptor. E ndocr Rev, 1995,16:143
8. Nomura M, Kinoshita S. (3-substituted benzyl) thiazolidine-2,4-diones as structurally new antihyperglycemic agents. Bioorg Med Chem Lett, 1999,9:533
9. Hasegawa I, Murakawa H, Suzuki M et al. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril, 1999,71:323
10. Robinson S, Henderson A D, Gelding S V et al. Dyslipidemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol, 1996,44:277
11. Meirow D, Raz I, Yossepowitch O et al. Dyslipidemia in polycystic ovarian syndrome, different groups, different aetiologies? Hum Reprod, 1996,11:1848
12. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of NIDDM. Am J Med, 1995,98:33